Last Update 11 Apr 26
NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout
Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations.
Analyst Commentary
Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations. Their commentary highlights both opportunity and execution risk for investors to monitor.
Bullish Takeaways
- Bullish analysts view the higher price target as consistent with revised long term growth assumptions, indicating they see the current share price as not fully reflecting their updated revenue outlook.
- Improved margin assumptions are a key factor in their models, with the view that better profitability, if achieved, could justify a higher earnings base and support the raised target.
- Reassessment of future P/E expectations indicates that bullish analysts are comfortable assigning a stronger multiple to Ingevity, based on their assessment of the company’s earnings profile and business mix.
- Adjustments to discount rates in their discounted cash flow analysis suggest increased confidence in the risk profile they assign to Ingevity’s cash flows, which supports a higher valuation input.
Bearish Takeaways
- Bearish analysts remain cautious that the updated long term revenue growth assumptions may be difficult to meet if end markets or pricing power do not follow the more optimistic scenarios used in models.
- Higher margin assumptions leave less room for error, so any cost pressures or weaker product mix could create a gap between modeled and realized profitability.
- Relying on richer future P/E expectations introduces valuation risk, particularly if earnings quality or consistency does not align with the levels implied in current targets.
- Changes to discount rates can work in both directions, and some cautious analysts note that any shift in perceived risk could quickly reduce the implied value from current forecasts.
What's in the News
- The company reported long lived assets impairment charges of $109.3 million for the fourth quarter ended December 31, 2025, which will flow through reported earnings for that period (Key Developments).
- Ingevity provided full year 2026 earnings guidance, with expected net sales in a range of $1.1b to $1.2b, giving you a reference point for upcoming revenue expectations (Key Developments).
- Between October 1, 2025 and December 31, 2025, Ingevity repurchased 615,736 shares for $30.89 million, completing a total buyback of 3,113,613 shares for $202.5 million under the program announced on August 2, 2022 (Key Developments).
Valuation Changes
- Fair Value: $79.25 remains unchanged, so the target output of the model is stable versus prior assumptions.
- Discount Rate: The discount rate has fallen slightly from 8.21% to about 8.10%, implying a modestly lower required return in the updated model.
- Revenue Growth: The revenue growth input is effectively unchanged at about 105.56%, so analysts are keeping the same top line growth assumption.
- Net Profit Margin: The net profit margin assumption is essentially stable at about 17.05%, indicating no material shift in the profitability outlook used in the model.
- Future P/E: The future P/E multiple has edged down slightly from about 15.15x to about 15.10x, reflecting a marginally lower valuation multiple applied to earnings.
Key Takeaways
- Strategic divestitures and operational optimization drive focus on high-value specialty chemicals, boosting margins, efficiency, and free cash flow resilience.
- Innovation investment and global expansion into sustainable applications support long-term growth, business diversification, and margin stability.
- Ongoing segment weakness, trade uncertainties, portfolio shifts, and rising competition threaten margin stability, revenue growth, and future earnings reliability.
Catalysts
About Ingevity- Manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America.
- Accelerated portfolio repositioning and the advanced-stage divestiture of non-core, lower-margin businesses (Industrial Specialties and CTO refinery) are expected to drive a step-change in margin profile, enabling greater focus and capital allocation toward higher-growth, value-added specialty chemicals-supporting both revenue quality and sustained EBITDA margin improvement.
- Substantial investments in innovation and engineered additives, especially in applications such as EV battery materials (via the Nexeon partnership) and process purification, position Ingevity to capture new demand arising from the increased global focus on sustainability and decarbonization-providing future top-line growth opportunities as industries transition to green technologies.
- Structural optimization of operational footprint, resulting in lower maintenance CapEx and improved manufacturing efficiency, is freeing up cash flow while lowering cost per unit, directly enhancing free cash flow generation and improving net earnings resiliency.
- Pricing power in high-value Performance Materials, supported by long-standing customer relationships and differentiated proprietary technologies, continues even in soft-volume environments and tariff uncertainty-demonstrating business resilience and enabling above-average net margin retention.
- Organic and geographic expansion plans, paired with ongoing portfolio review targeting high-growth applications and regions (such as Asia-Pacific and green infrastructure), are expected to reduce cyclicality and broaden the addressable market, positively impacting future revenue diversification and long-term earnings stability.
Ingevity Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Ingevity's revenue will grow by 1.1% annually over the next 3 years.
- Analysts assume that profit margins will increase from -12.9% today to 17.1% in 3 years time.
- Analysts expect earnings to reach $205.5 million (and earnings per share of $6.75) by about April 2029, up from -$150.3 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 15.6x on those 2029 earnings, up from -17.6x today. This future PE is lower than the current PE for the US Chemicals industry at 29.4x.
- Analysts expect the number of shares outstanding to decline by 3.22% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 8.1%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- APT (Advanced Polymer Technologies) segment suffered a non-cash goodwill impairment charge of $184 million this quarter, with ongoing tariff-related uncertainty and persistent weakness in global industrial markets leading to reduced demand and lower EBITDA margins (now guided only at 15–20%), threatening long-term revenue and margin stability.
- Company remains exposed to cyclical downturns in key industrial and automotive end-markets-recent headwinds in Europe and Asia and cautious auto production forecasts outside China highlight vulnerability to macroeconomic and regulatory shifts, impacting long-term revenues and earnings.
- Indirect and direct tariff impacts have meaningfully reduced customer demand, especially in global APT markets like automotive, footwear, and apparel-prolonged tariff uncertainties and shifts in global trade patterns could further erode future revenues and net margins.
- The company's reliance on legacy segments (e.g., activated carbon, pine-chemical-derived products) and ongoing portfolio rationalization-such as the planned sale of the Industrial Specialties business and CTO refinery-adds business model uncertainty and may introduce future earnings volatility if asset divestitures or repositioning strategies fail to deliver anticipated synergies.
- Rising competitive pressures and the need for price concessions in the APT segment (in part to address global competitive dynamics) suggest risk of margin compression and potential loss of market share to more innovative or sustainable chemical producers, challenging long-term earnings growth.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $79.25 for Ingevity based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.2 billion, earnings will come to $205.5 million, and it would be trading on a PE ratio of 15.6x, assuming you use a discount rate of 8.1%.
- Given the current share price of $75.25, the analyst price target of $79.25 is 5.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Ingevity?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

